Table 2.
Partners’ disease characteristics
| Characteristic | Statistic |
|---|---|
| Age, mean (range), years | 32 (21–42) |
| Sex, n (%) | |
| Female | 10 (100) |
| Years diagnosed with RA, median (interquartile range) | 7 (4–17) |
| Parity, n (%) | |
| Multiparous | 5 (50) |
| Nulliparous | 5 (50) |
| Current medications taken for RA, n (%)a,b | |
| Conventional synthetic DMARDs | |
| Antimalarials (i.e. HCQ, chloroquine) | 8 (80) |
| MTX | 9 (90) |
| SSZ | 5 (50) |
| LEF | 2 (20) |
| Biologic and targeted synthetic DMARDs | |
| Anti-TNF agents | 7 (70) |
| Others (e.g. abatacept, rituximab, tocilizumab, tofacitinib) | 4 (40) |
| Used medication for RA during pregnancy, n (%) | 3 (60) |
a
Cumulative percentage can be >100, because multiple categories can be relevant to each participant. bMedications taken for RA by female patients at the time of their demographics survey.